Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
11:07am, Wednesday, 24'th Jul 2024
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN , July 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that it has completed a repricing of the approximately $2.7 billion outstanding
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
01:58pm, Friday, 19'th Jul 2024
When I think of biotech stocks, I imagine volatile share prices and plenty of red ink. I also think of big-time shareholder returns for the industry's winners.
Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
04:15pm, Wednesday, 17'th Jul 2024
DUBLIN , July 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024, after the clos
Add These 5 Hot Biotech Stocks In July
09:22am, Wednesday, 17'th Jul 2024
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing
Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?
09:30am, Thursday, 11'th Jul 2024
Investors need to pay close attention to JAZZ Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
07:45am, Tuesday, 09'th Jul 2024
Ms. Pearce brings over 30 years of commercial experience and track record of success across global markets DUBLIN , July 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced
3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their Potential
08:09am, Thursday, 04'th Jul 2024
Through the first half of 2024, you couldn't blame investors for having a sense of deja vu. Technology stocks, and particularly AI stocks, are where the alpha has been for growth-oriented investors.
7 Biotech Stocks to Boost Your Portfolio to Peak Health
02:11pm, Wednesday, 26'th Jun 2024
While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if
3 Cannabis Stocks That Could Make Your Grandchildren Rich
03:39pm, Tuesday, 25'th Jun 2024
With the federal government taking steps to reschedule cannabis to Schedule III, effectively creating a form of medical cannabis legalization, the future of cannabis stocks is under intense scrut
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
09:36am, Friday, 21'st Jun 2024
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
09:15am, Friday, 21'st Jun 2024
Jazz Pharmaceuticals plc's suvecaltamide failed in a phase 2b trial for essential tremor, but this is a minor setback for the company and one that should have been expected. The oxybate franchise is p
2 Pharma Stocks Moving in Different Directions Today
01:43pm, Thursday, 20'th Jun 2024
Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level.
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
12:29pm, Thursday, 20'th Jun 2024
Thursday, Jazz Pharmaceuticals plc JAZZ released topline results from the Phase 2b trial evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study
07:57am, Thursday, 20'th Jun 2024
Jazz Pharmaceuticals said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed to meet the main goal in a mid-stage study.
